Acetyl-3,5-dibromosalicylic acid (dibromoas irin) is shown to be a potent acylating agent of intracellular hemoglobin in vitro. Transfer of the actyl group of dibromoaspirin to amino groups of hemoglobins A and S seems to occur predominantly at just two or three sites on these proteins. This acetylation produces moderate increases in the oxygen affinities of normal and sickle erythrocytes. Furthermore, treatment of intracellular hemoglobin S with dibromoaspirin directly inhibits erythrocyte sickling. This antisickling effect is paralleled by an increase in the minimum gelling concentration of deoxy hemoglobin S extracted from sickle erthrocytes that had been exposed to low concentrations of dibromoaspirin. These observations suggest that dibromoaspirin might be an effective antisickling agent in vivo.
sickling effect is paralleled by an increase in the minimum gelling concentration of deoxy hemoglobin S extracted from sickle erthrocytes that had been exposed to low concentrations of dibromoaspirin. These observations suggest that dibromoaspirin might be an effective antisickling agent in vivo.
On deoxygenation, hemoglobin S (Hb S) aggregates into helical fibers that precipitate from solution as a gel (1, 2) . Within the erythrocyte, these fibers distort the cell into various abnormal shapes, among which is the characteristic sickled form. Although other abnormalities of the erythrocyte have been described in patients having sickle cell anemia (3-5), the aggregation of deoxy Hb S represents the principal pathologic process underlying the disease.
It has occurred to a number of investigators that the aggregation of deoxy Hb S might be inhibited by chemical modification of the protein (6) (7) (8) (9) (10) (11) . Of the different functional groups in the side chains of this protein, the amino group seems particularly attractive because it can be modified with relatively mild reagents that might be pharmacologically acceptable. One category of such reagents includes compounds such as cyanate (6, 12) and aspirin (8, 13, 14) , which carbamylate and acylate hemoglobin, respectively, A second group, aldehydes, form Schiff base adducts with amines of the protein (9, (15) (16) (17) (18) (19) (20) . Cyanate (6, 12) and a number of aromatic aldehydes (18, 20) have been shown to inhibit erythrocyte sickling in vitro. These compounds exert their antisickling effects by increasing the oxygen affinity of Hb S, thereby decreasing the fraction of Hb S in the deoxy form. At fixed percentages of saturation of hemoglobin with oxygen, however, these compounds have no significant influence on sickling.
The finding that aspirin acetylates amino groups of intracellular hemoglobin We report here that a compound modified in the leaving moiety, acetyl-3,5-dibromosalicylic acid (A), is a very effective acylating agent of intracellular hemoglobin. Acetylation appears to occur at relatively specific sites on the protein. The compound inhibits significantly the gelation of cell-free deoxy Hb S and erythrocyte sickling.
EXPERIMENTAL PROCEDURES
Materials. 3,5-Dibromosalicylic acid was obtained from Aldrich Chemical Co. Acetyl-3,5-dibromosalicylic acid (dibromoaspirin) was prepared by the sulfuric acid-catalyzed reaction of 3,5-dibromosalicylic acid with a 2.5-fold excess of acetic anhydride. When the reaction mixture was poured into ice water, the product separated as a white solid: mp 152-153.5°( recrystallized from benzene); lit. 1560 (23) Reactions of intracellular and cell-free hemoglobin with dibromoaspirin were carried out according to'described procedures (20) . Additional studies were performed in which treated erythrocytes were centrifuged at hourly intervals and immediately resuspended in fresh buffer containing dibromoaspirin. All reactions were run at 37'.
The chemically modified hemoglobins were examined by gel isoelectric focusing as described (20) . The modified species 'appeared in the gel at positions anodal to unmodified hemoglobin. After electrofocusing, gels were fixed in 15% trichloroacetic acid to prevent diffusion of the sharply focused bands. The extent of modification was quantitated by integration of peaks in densitoinetric scans of the gels.
Oxygen binding studies and tests in Vitro for antisickling activity were conducted as described (20) . In sickling experiments, 20% suspensions pf erythrocytes were first treated with dibromoaspirin in isotonic phosphate buffer. The erythrocytes were then washed once in isotonic phosphate buffer and once in fresh, previously frozen human AB plasma and were finally resuspended in the latter to the original hematocrit value.
Minimum gelling concentrations (MGCs) were determined according to the procedure of Bookchin and Nagel (24) . Measurements were made in parallel on untreated Hb S and on Hb S extracted from erythrocytes after exposure to 5 mM dibromoaspirin for 2 hr at 370 in isotonic phosphate buffer. To ensure complete deoxygenation, samples were exposed to partially humidified N2 for a minimum of 1 hr. Several determinations were made on each hemoglobin sample, MGC values were reproducible to within 0.5 g/dl.
RESULTS
The reaction of 5 mM dibromoaspirin with a 20% suspension of normal erythrocytes in isotonic phosphate buffer pH 7.2 at 370 for 2 hr led to the modification of 70-80% of the hemoglobin. At these low concentrations, aspirin yields no detectable modification. A densitometric scan of an isoelectrically focused gel on which the hemoglobins species were separated is shown in Fig. 1 . The bands appear as a series of doublets. The bands marked 1, 2, and 3 represent approximately 80% of the modified species.
Under the same conditions but with intracellular Hb S, the reaction with 5 mM dibromoaspirin led to 60% modification of the protein. Isoelectric focusing of modified Hb S gave a series of bands identical in pattern to that observed for modified normal adult hemoglobin (Hb A).
To provide evidence that modification of hemoglobin by dibromoaspirin is due to covalent alteration by transacetylation, the reactions of the nonacetylated phenol, 3,5-dibromosalicylic acid, and of dibromoaspirin, at concentrations of 5 mM, with a 6% solution of cell-free Hb'A were compared. Under these conditions, dibromoaspirin yielded essentially the same level of modification, 70-80%, as observed for the reaction with intracellular Hb A. On the other hand, with nonacetylated 3,5-dibromosalicylic acid, no modification was found.
Kinetic studies of the reaction between 5 mM dibromoaspirin and intracellular Hb A, as a 20% suspension of erythrocytes in isotonic phosphate buffer, revealed that 70-80% modification is achieved within 30 min. After that interval of time, no further increase in the extent of modification occurred and there was no change in the pattern of modified species separated by isoelectric focusing. Because this level of modification represents the utilization of less than 3 mM dibromoaspirin,* the remainder is presumably lost by hydrolysis. The equilibrated with a gas mixture containing 0.5% 02, 5% C02, and the balance N2 (PO2 = 3 mm Hg) prior to fixation in isotonic 2% formalin.
(X406.) dipolar interactions of the aromatic C-Br bond with loci of cationic lysyl residues in the hemoglobin macromolecule. The resolution of the dibromoaspirin-modified hemoglobin species by isoelectric focusing indicates that certain amino groups on the protein are modified preferentially. The three well-focused bands nearest unmodified Hb A (bands 1, 2, and 3 in Fig. IB) account for approximately 80% of the modification. The sharpness of these bands suggests that each is due to a single hemoglobin species. Bands 1 and 2 probably contain protein that has been acetylated at a single site per dimer.t Band 3 may also correspond to a singly modified component. Alternatively, as suggested by the pattern of doublets observed in the densitometric scan of the gel, band 3 may be due to a doubly labeled derivative, acetylated at sites modified in both bands 1 and 2. In any event, acetylation by dibromoaspirin occurs predominantly at just 2 or 3 of the 23 distinct amino groups per hemoglobin dimer. This high degree of specificity is consistent with the notion that the enhanced activity of dibromoaspirin is due to binding by hemoglobin.
Modification of erythrocytes with dibromoaspirin increases the oxygen affinity of intracellular Hb A and Hb S to a quantatively similar extent (Fig. 2) . This increase in oxygen affinity in itself decreases erythrocyte sickling at intermediate oxygen tensions because the fraction of Hb S in the deoxygenated form is decreased. Similar findings have been reported with cyanate (6, 12) and with various aromatic aldehydes (18, 20) . These reagents, like dibromoaspirin, influence oxygen binding by modifying amino groups on the protein.
In addition to the effects on oxygen binding, treatment with dibromoaspirin directly inhibits erythrocyte sickling. That is, at equivalent oxygen saturation, the fraction of cells in the sickled conformation is decreased by treatment with dibromoaspirin. This is illustrated in plots (Fig. 3) of the percentage sickling versus oxygen saturation for untreated cells and for cells treated with 5 mM dibromoaspirin. The photomicrographs in Fig. 4 , of treated and untreated erythrocytes at low oxygen saturation, reveal further the marked inhibition of erythrocyte sickling with dibromoaspirin. That this effect is due to acetylation of Hb S is supported by the observation that the MGC for deoxy Hb S extracted from treated erythrocytes is significantly increased (Table 1) .
In all of these studies, approximately 60% of the Hb S had been modified by dibromoaspirin. At (27, 28) .
Another approach that seems particularly promising, in th light of work on the binding of aldehydes to hemoglobin b Schiff base linkages (7, 15, 20) , is to combine within a singl reagent the potential for Schiff base formation with that fo transacylation. For 
